Related Experiment Video
Updated: Jan 27, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Topical Fisionerv® is effective in treatment of peripheral neuropathic pain
Angelo Tarullo1, Antonella Tarullo, Emanuela Lacatena
1Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.. angelo.tarullo@libero.it.
Background:
Management of neuropathic pain (Neu P) is complex and difficult. Although there are several therapeutic options, treatment with Neu P is often inadequate, which led to undertreated patients. Thus, it would be desirable, for Neu P treatment, further multimechanistics approaches.
Objective:
The aim of the present study was to evaluate, in Neu P management, the effectiveness of "FISIONERV, a gel for topical use.
Setting:
This study was conducted in the "Rehabilitation Unit of N. Melli's Hospital, Brindisi, Italy".
Patients And Intervention:
In this study a double- blind randomized controlled clinical trial was conducted over 8-week treatment on 58 outpatients affected by Neu P caused by lumbar sciatica or lumbar disk herniation and/or lumbar canal stenosis (31 subjects), or with carpal tunnel syndrome (27 subjects), randomly assigned to the following two groups: Group A; n=29, received (fisionerv® gel, 3 times/day) added to physiotherapy (forty minutes-daily session). Group B; n=29 received a vehicle gel (placebo, 3 times/day) added to physiotherapy (forty minutes-daily session).
Measurements:
Pain was assessed by a visual analogue scale (VAS). Neuropathic symptoms frequency (pain, burning, paraesthesiae and numbness) were scored at baseline and at the end of the treatment. Treatment compliance and safety were also evaluated.
Results:
Both groups experienced a significant reduction in VAS and neuropathic symptoms after 8-treatment weeks. However, a significant (p<0.05) improvement was observed in group A (VAS mean 5.3 (1.10) with respect to group B (VAS mean=6.17 (0.80), already after 4 weeks of treatment. A further VAS reduction was recorded at 8 treatment weeks, with significant difference between the treatments (group A: VAS mean=1.89 (0.77); group B: VAS mean=3.79 (1.20) (p<0.001). In addition, more patients of the group A, than in group B, reported an improvement of their neurophatc pain (p<0.01). No adverse drug reaction was observed.
Conclusion:
Use of fisionerv®, in combination with physiotherapy, resulted a useful approach to NP treatment.
Clinical Rehabilitation Impact:
These preliminary observations suggest that some interesting goals (better pain control and physical wellbeing) could be achieved by a multimodal therapy in NP patients.
Related Concept Videos
Pain
Analgesia and Pain Management
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation
Primary Motives: Sleep, Sex, and Pain Avoidance
Sleep is a fundamental physiological drive that fosters a state of restfulness crucial for several bodily functions. It facilitates body restoration, the process by which the body repairs, rejuvenates, and maintains itself during sleep, including memory...

